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Abstract: <jats:bold>Background</jats:bold> Cerebral folate deficiency (CFD) syndrome is charac-
terised by a low concentration of 5-methyltetrahydrofolate in cerebrospinal fluid, while folate levels in
plasma and red blood cells are in the low normal range. Mutations in several folate pathway genes, includ-
ing <jats:italic>FOLR1 (folate receptor alpha</jats:italic>, <jats:italic>FR฀)</jats:italic>, <jats:italic>DHFR
(dihydrofolate reductase)</jats:italic> and <jats:italic>PCFT (proton coupled folate transporter</jats:italic>)
have been previously identified in patients with CFD.<jats:bold>Methods</jats:bold> In an effort
to identify causal mutations for CFD, we performed whole exome sequencing analysis on eight CFD
trios and identified eight de novo mutations in seven trios.<jats:bold>Results</jats:bold> Notably,
we found a de novo stop gain mutation in the <jats:italic>capicua</jats:italic> (CIC) gene. Us-
ing 48 sporadic CFD samples as a validation cohort, we identified three additional rare variants in
CIC that are putatively deleterious mutations. Functional analysis indicates that CIC binds to an oc-
tameric sequence in the promoter regions of folate transport genes: <jats:italic>FOLR1</jats:italic>,
<jats:italic>PCFT</jats:italic> and <jats:italic>reduced folate carrier (Slc19A1; RFC1</jats:italic>).
The <jats:italic>CIC</jats:italic> nonsense variant (p.R353X) downregulated FOLR1 expression in
HeLa cells as well as in the induced pluripotent stem cell (iPSCs) derived from the original CFD proband.
Folate binding assay demonstrated that the p.R353X variant decreased cellular binding of folic acid in
cells.<jats:bold>Conclusion</jats:bold> This study indicates that <jats:italic>CIC</jats:italic> loss
of function variants can contribute to the genetic aetiology of CFD through regulating <jats:italic>FOLR1</jats:italic>
expression. Our study described the first mutations in a non-folate pathway gene that can contribute to
the aetiology of CFD.
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ABSTRACT
Background Cerebral folate deficiency (CFD) 
syndrome is characterised by a low concentration of 
5- methyltetrahydrofolate in cerebrospinal fluid, while 
folate levels in plasma and red blood cells are in the low 
normal range. Mutations in several folate pathway genes, 
including FOLR1 (folate receptor alpha, FRα), DHFR 
(dihydrofolate reductase) and PCFT (proton coupled 
folate transporter) have been previously identified in 
patients with CFD.
Methods in an effort to identify causal mutations for 
CFD, we performed whole exome sequencing analysis on 
eight CFD trios and identified eight de novo mutations in 
seven trios.
Results notably, we found a de novo stop gain 
mutation in the capicua (CiC) gene. Using 48 sporadic 
CFD samples as a validation cohort, we identified 
three additional rare variants in CiC that are putatively 
deleterious mutations. Functional analysis indicates that 
CiC binds to an octameric sequence in the promoter 
regions of folate transport genes: FOLR1, PCFT and 
reduced folate carrier (Slc19A1; RFC1). The CIC nonsense 
variant (p.r353X) downregulated FOlr1 expression in 
hela cells as well as in the induced pluripotent stem cell 
(iPsCs) derived from the original CFD proband. Folate 
binding assay demonstrated that the p.r353X variant 
decreased cellular binding of folic acid in cells.
Conclusion This study indicates that CIC loss of function 
variants can contribute to the genetic aetiology of 
CFD through regulating FOLR1 expression. Our study 
described the first mutations in a non- folate pathway 
gene that can contribute to the aetiology of CFD.
INTRODUCTION
Cerebral folate deficiency (CFD) is defined as 
any neurological syndrome associated with low 
5- methyltetrahydrofolate (5- MTHF) concentra-
tions in cerebrospinal fluid (CSF), while folate 
concentrations in serum are typically in the low 
normal range.1 In humans, the folate concentration 
in the CSF is normally ≥1.5- fold higher than in 
serum. As folate is essential for normal development 
and production of the biogenic amines and pterins 
in the central nervous system, prenatal and post-
natal folate deficiency produces a variety of neuro-
logical symptoms, including intellectual disability, 
epilepsy, ataxia and pyramidal tract signs.2 Folate is 
absorbed into the bloodstream via the gastrointes-
tinal tract mainly through two uptake systems: the 
reduced folate carrier 1 (RFC1; SLC19A1) and the 
proton- coupled folate transporter (PCFT).3 From 
the bloodstream, folate binds to the folate receptor 
alpha (FRα/FOLR1) on the basolateral endothelial 
surface of the choroid plexus. Through receptor- 
mediated endocytosis and transcytosis, folate is 
then transported across the blood- CSF- barrier 
into the CSF.4 FOLR1 is highly expressed in the 
choroid plexus, and it has a higher affinity to folic 
acid (FA) at neutral pH compared with other folate 
transporters, such as PCFT and RFC1.5 These two 
characteristics are important factors in building and 
keeping higher folate concentrations in the CSF 
than in serum. Previous studies demonstrated that 
dysfunctional FOLR1, such as that which could be 
the result of either FOLR1 mutations6 7 or FOLR1 
autoantibodies,8 can result in CFD. Mutations in 
other folate related genes, such as DHFR9 10 and 
PCFT,11 12 are also reported to be associated with 
low 5- MTHF CSF concentrations. We previously 
reported a patient carrying a de novo truncating 
CIC mutation.13 The patient presented with a paedi-
atric B- cell acute lymphoblastic leukaemia (B- ALL) 
and was treated with methotrexate (MTX). She 
developed a spectrum of neurobehavioral disor-
ders including signs of autistic spectrum disorder, 
seizures, loss of language and motor skills and had 
CFD, even after cancer remission and the discontin-
uation of MTX treatment.
The CIC gene was originally discovered in 
Drosophila, where it was shown to be highly 
expressed in the head and tail region,14 which 
resulted in the naming of it ‘head and tail’ or 
‘capicua’ in Catalan. It is a transcriptional repressor 
of the high mobility group (HMG)- box family, 
which binds a specific octameric DNA sequence, 
T(G/C)AATG(A/G)A, in the genome via their 
HMG- box and C1 domain.15 CIC is known to be 
transported into the nucleus by KPNA3, a nuclear 
importin protein that can interact with CIC at its 
C- terminal nuclear localisation signal domain.16 
It was found to function downstream of the EGF- 
RTK- RAS- ERK- MAPK signalling pathway to 
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studies also indicated CIC influences Toll/Interleukin-1 signal-
ling.17 The most well- known CIC downstream target genes 
include polyomavirus enhancer activator 3 family members 
genes, ETV1, ETV4 and ETV5 as well as matrix metalloproteinase 
9 (MMP9)18 and MMP24.19 In the absence of EGFR- ERK signal-
ling, CIC binds to and represses those genes, while activation of 
the pathway results in inactivation of CIC through phosphor-
ylation induced degradation or relocalisation from the nucleus 
to the cytoplasm.20–23 In mammals, CIC forms a transcriptional 
repressor complex with ataxin-1, a gene that contributes to the 
pathogenesis of spinocerebellar ataxia type 1.24 Conventional 
Cic knockout (KO) mice present with omphalocele, abnormally 
small litter size and lung differentiation defects that result in 
perinatal lethality.18 25 In early development, mice with a condi-
tional CIC KO display impaired forebrain neurodevelopment, 
resulting in hyperactivity, decreased learning ability and impaired 
memory.13 In adult mice, systemic conditional CIC inactivation 
induces T- cell acute lymphoblastic lymphoma. CIC was also 
reported to modify peripheral immune tolerance by suppressing 
aberrant activation of adaptive immunity.26 In humans, CIC 
mutations have been associated with several diseases, including 
neurobehavioral phenotypes,13 oligodendroglioma,27 lung carci-
noma19 and prostate cancer.28
Although studies have reported that mutations in human CIC 
are strongly associated with ALL and neurobehavioral pheno-
types, studies to date have failed to determine whether CIC 
mutations contribute to the aetiology of CFD. In fact, there are 
no comprehensive trio- based genetic studies on patients with 
CFD. Since the aforementioned patient who carries the trun-
cated CIC mutation does not seem to carry any rare variant in 
known CFD genes (FOLR1, PCFT and RFC1) in our whole 
exome sequencing (WES) dataset, we propose that the truncated 
CIC protein may play a role in CFD progression. Thus, CFD 
may be caused from genetic factors other than variants in known 
folate transport genes. In order to better understand the aeti-
ology of CFD, a comprehensive genetic profiling of patients with 
CFD is definitely required, followed by a validation of whether 
CIC gene mutation contributes to CFD. Herein, we performed 
WES on eight CFD trios and 48 sporadic patients with CFD. 
We identified eight de novo mutations in seven different trios. 
Among the cohort of 48 sporadic patients with CFD, we iden-
tified another three CIC rare deleterious mutations. Finally, 
we performed functional assays on the de novo truncated 
CIC variant and showed that the truncated CIC dysregulates 
the folate transport genes in HeLa and patient- derived human 
iPSCs. Overall, our results provided the first trio- based genetic 
analysis on patients with CFD and enhanced our understanding 
of a new CFD aetiology.
MATERIALS AND METHODS
Human subjects
The original CFD proband in this study was collected through 
self- referral by the mother of the patient. An additional 48 
cases were collected with (10) or without (38) our ability to 
obtain parental biological samples. Folate concentrations in 
CSF were measured at the treating hospitals. DNA samples of 
48 CFD cases from various genetic and neuropaediatric clinics 
in Germany, Finland, Italy, Switzerland, The Netherlands, UK 
and the USA were reported in our previous publication.7 This 
study was approved by institutional review board of The Univer-
sity of Texas at Austin. All samples were collected with written 
informed parental consent.
Sequencing analysis of DNA samples
DNA sequencing libraries were built using NEBNext Ultra 
DNA Library Prep Kit (New England Biolabs) following proto-
cols as described by the manufacturer (V.3.0). The Agilent Sure-
Select Human All Exon V5 (Agilent Technologies) was used for 
exome enrichment. Libraries were sequenced by the Genome 
Sequencing and Analysis Facility at University of Texas at 
Austin using an Illumina Hi- Seq 2000 platform (Illumina). 
Next generation sequencing data were analysed following 
GATK Best Practices (https:// software. broadinstitute. org/ gatk/ 
best- practices/). Briefly, FASTQ format data were mapped to 
hg19 using BWA alignment software,29 sorted and indexed by 
SAMtools,30 base recalibrated by GATK31 and duplicate reads 
removed by Picard software (https:// broadinstitute. github. 
io/ picard/). Variants were called using GATK Haplotype-
Caller methods. De novo variant analysis was performed by 
TrioDeNovo software.32 Variants annotation was performed 
with Annovar.33 Sanger sequencing was performed following 
previously published primers and protocols.34 CIC sequencing 
primers are in online supplementary table 1. Polyphen2, SIFT 
and CADD scores were used for predicting variants’ func-
tion.35–37 The gnomAD database was used for examining the 
allele frequency of each mutants.38
Plasmid preparation and siRNA information
GFP- CIC and HA- KPNA3 plasmids were provided to us by Dr 
Carol MacKintosh at the University of Dundee. CIC variant 
was introduced into the GFP- CIC plasmid using the GeneArt 
Site- Directed Mutagenesis System (Cat# A14604, Thermofisher 
Scientific). Ataxin-1 plasmids were provided by Dr Huda Zoghbi 
at Baylor College of Medicine (Addgene Cat# 48189).
Full- length human CIC and CIC variant were inserted via 
EcoRI/SalI into the expression vector pLVX- IRES- puro (Takara 
Bio) containing an EGFP ORF. Vectors for production of lentiviral 
particles pMD2.G and psPAX2 were from Addgene (plasmids 
Cat# 12259, Cat# 12260; deposited by Didier Trono). pGL3- 
basic was obtained from a commercial source (Promega). FOLR1 
promoter region was PCR amplified and inserted into pGL3- 
basic by subcloning. ON- TARGET plus SMARTpool targeting 
the CIC gene, including four individual siRNAs (GCUUAGUGU-
AUUCGGACAA, CGGCGCAAGAGACCCGAAA, GAGAAG-
CCGCAAUGAGCGA and CGAGUGAUGAGGAGCGCAU) 
were purchased from Dharmacon as previously reported.16 The 
scrambled universal negative siRNA control was purchased from 
Sigma- Aldrich (Cat# SIC005).
Generation of stable cell lines and subcellular localisation 
analysis
For virus production, HEK293T cells were cotransfected with 
pMD2.G, psPAX2 and pLVX- GFP- puro plasmids containing 
CIC WT or CIC mutant p.R353X using a calcium phosphate 
method. After 48 hours, viral supernatants were collected, 
passed through a 0.45 µm PES- membrane filter and precipi-
tated using polyethylene glycol 6000. Lentivirus infection was 
performed in the presence of 5 µg/mL polybrene. Infected 
HeLa and Caco-2 cells were selected with puromycin (1 µg/
mL). HeLa cells and Caco-2 cells stably expressing GFP- CIC 
wildtype, GFP- CIC p.R353X or GFP (control) were fixed with 
paraformaldehyde on cover slips. Subcellular localisation was 
analysed by laser scanning confocal microscope (LSM710; 
Leica, Wetzlar, Germany) for GFP and endogenous CIC. Nuclei 
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Coimmunoprecipitation and immunoblot analysis
The effect of p.R353X on CIC interaction with KPNA3 and 
ATXN1 was analysed following previously published proto-
cols.16 24 Briefly, wildtype or p.R353X mutant GFP- CIC and 
KPNA3 or ATXN1 plasmid were cotransfected into HEK293T 
cells. 24 hours post- transfection, the cells were harvested using 
RIPA lysis buffer. Co- IP and immunoblot GFP antibody was 
purchased from ThermoFisher (Cat#A-11120). KPNA3 anti-
body was purchased from Bethyl Laboratories (Montgomery, 
Texas, USA).
CIC p.R353X mutant regulation of FOLR1, PCFT, RFC1 gene 
expression was analysed by immunoblotting assays using FOLR1 
antibody (Mov18), PCFT antibody (Abcam) and RFC1 antibody 
(Santa Cruz Biotechnology) and β-actin antibody (Cat# 8- 7A5, 
Developmental Studies Hybridoma Bank at the University of 
Iowa).
Folic acid (FA) binding assay and FA concentration 
measurement
FA binding assay was performed according to previously 
published methods.7 Briefly, HeLa cells stably expressing GFP, 
GFP- CIC WT or GFP- CIC R353X were exposed for 15 min 
to 5 nmol/L [3H] FA (Moravek Biochemicals) in the presence 
or absence of 500 nmol/L non- labelled FA. After three ice- cold 
Hank’s balanced salt washes, cell surface bound labelled FA was 
released with acid buffer and measured on a liquid scintillation 
spectrometer. Specific FA binding was calculated from the differ-
ence between [3H] FA bound in the presence and absence of 500 
nmol/L non- labelled FA. Stable transfected HeLa cells from 
an additional well were lysed with 0.2 M NaOH and protein 
amount was determined by using the BCA protein kit (Pierce). 
GFP was used as control. FA concentrations in H9 stem cell and 
human iPS cells were measured using FA ELISA kit (BioVision).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) was performed 
following the published protocol of Nelson et al.39 Briefly, 
cells were cross- linked with formaldehyde and then lysed by IP 
buffer (150 mM NaCl, 50 mM Tris- HCL(PH7.5), 5 mM EDTA, 
NP-40 (0.5% vol/vol), Triton X-100 (1.0% vol/vol)). The cell 
lysis containing nuclear pellets was isolated and sheared using 
a Misonix Sonicator 4000 (Qsonica LLC, Newtown, CT) by 
pulsing samples in cold water in a 5.5 inch cup horn 15 times 
at an amplitude of 60 for 20 s with 30 s rests in between pulses. 
Chromatin samples were separated into two parts, one part 
incubated with CIC antibody (provided by Dr Huda Zogbhi), 
and the other part incubated with IgG antibody (Santa Cruz 
Biotechnology) as a negative control. Protein A beads were used 
to precipitate the chromatin- protein- antibody complex. ChIP 
and total DNA were purified using Chelex-100 (Bio- Rad, cat. 
no. 142-1253) following Nelson and colleagues’ protocol.33 The 
purified DNA was subjected to quantitative real- time PCR (qRT- 
PCR), using specific primers for the promoter of the endogenous 
FOLR1, PCFT, RFC1 genes. The sequences of qRT- PCR primers 
are provided in online supplementary table.
Luciferase assay
FOLR1 promoter region containing CIC binding motif(s) 
were PCR amplified and subcloned into a pGL3- Basic vector. 
HeLa cells were grown in Dulbecco's Modified Eagle Medium 
(DMEM) medium supplemented with 10% FBS and 1% peni-
cillin & streptomycin (P/S) solution. Cells were seeded in 24- well 
plates 1 day before transfection. After 24 hours in culture, the 
cells (70%–80% confluence) were transfected with 1 µg of GFP- 
CIC plasmids, pGL3 plasmids and 20 ng of the pRL- TK plasmid 
as internal control with Lipofectamine 2000 (ThermoFisher 
Scientific). After another 24 hours of culture, the transfected 
cells were lysed in 0.5 mL lysis buffer (Promega), incubated on 
ice for 10 min and then centrifuged at 5000 rpm for 5 min. The 
supernatant (50 µL) was then assayed for luciferase activity with 
the Dual- luciferase Reporter Assay using BioTek Synergy HT 
Multi- Mode Microplate Reader (BioTek Instruments, Winooski, 
Vermont, USA). Three independent transfection experiments 
were performed in triplicate for each assay.
Patient fibroblast culture and inducing pluripotent stem cells 
(iPSC)
The skin sample was harvested under the guidelines approved 
by the Institutional Review Board of The University of Texas 
at Austin and the Seton Family of Hospitals. Fibroblasts from 
the skin biopsy were cultured in the IMDM (Iscove’s Modified 
Dulbecco’s Medium) supplemented with 10% FBS (Fetal bovine 
serum) and 1% P/S solution in normal cell culture condition 
(37°C and 5% CO
2
) and frozen in liquid nitrogen for preserva-
tion. An aliquot containing 105 fibroblasts were reprogrammed 
on the third passage by introducing the four Yamanaka factors 
(Oct4, Sox2, Kif4, c- Myc)40 using CytoTune- iPS 2.0 Sendai 
Reprogramming Kit (ThermoFisher Scientific) following the 
protocol guidelines provided by the manufacturer. The medium 
was changed every 24 hours after transduction for 6 days. 
On the 7th day, the cells were harvested using 0.05% trypsin/
EDTA and plated on dishes with γ-irradiated mouse embryonic 
fibroblasts in human embryonic stem cell medium (KO DMEM 
supplemented with 20% KO serum, 2 mM glutamax, 1% P/S, 
0.1 mM β-mercaptoethanol, 1% non- essential amino acids and 
10 ng/mL bFGF (ThermoFisher Scientific). After approximately 
14 days, iPSC colonies formed. Four colonies were picked manu-
ally and passaged for expansion, karyotyping and freezing. From 
the third passage, iPSC colonies were transferred to Matrigel 
coated plates with mTeSR1 medium (Stemcell) to maintain 
under feeder- free conditions. Karyotyping was performed by 
WiCell Research Institute in Madison, Wisconsin, USA. The 
absence of Sendai virus vector in iPSCs was verified by Applied 
Biosystems TaqMan iPSC Sendai Detection Kit (Applied Biosys-
tems A13640).
FOLR1 autoantibody detection
The assay for identification of the presence and relative quan-
tification of FOLR1 autoantibodies in serum samples was 
performed as previously published.41–43 Horseradish peroxidase 
(HRP) labelled anti IgG antibody (Cat#I8640 Sigma Aldrich) 
and IgM antibody (Cat#I8260, Sigma Aldrich) were used to 
detect IgG and IgM. Antibody- depleted sera (Sigma Aldrich) was 
used as negative control. Serum effect on blocking FA binding to 
folate binding protein was detected using HRP labelled FA (FA- 
HRP, Ortho- Clinical Diagnostics, Raritan, New Jersey, USA). FA 
in serum samples was removed as previously described.44 Unla-
belled FA was spiked (0.01–2000 ng/mL) into stripped antibody 
depleted sera to generate the standard curve. The SuperSignal 
ELISA Femto Substrate (Cat#37074, ThermoFisher Scientific) 
was used as substrate for detection of HRP activity. Images 
were collected using a 96- well imager (Q- View Imager, Quansys 
Biosciences). Intensities were extracted from the images using 
Q- View Software. IgG, IgM and relative FA- blocking amount 
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Table 1 Identification of de novo mutations in CFD trios
Sample Gene Exonic_Function AAChange SIFT Prediction PolyPhen2 Prediction
CFD6A ATP1A1 Non- synonymous SNV NM_000701:c.G1579A:p.E527K 0.04 D 0.002 B
CFD7A SGK223 Non- synonymous SNV NM_001080826:c.A308C:p.N103T 0.01 D 0.003 B
CFD8A RGPD2 Startloss SNV NM_001078170:c.T2C:p.M1T / / / /
CFD4A SLC5A9 Non- synonymous SNV NM_001011547:c.A1979G:p.H660R 0.45 T 0 B
CFD4A SLC35A2 Non- synonymous SNV NM_001042498:c.G991A:p.V331I 0 D 0.997 D
CFD9A ABCA12 Non- synonymous SNV NM_015657:c.G3539C:p.R1180T 0 D 0.997 D
CFD12A AKAP12 Non- synonymous SNV NM_144497:c.C2957T:p.S986L 0.25 T 0 B
CFD1A CIC Stopgain SNV NM_015125:c.C1057T p.R353X / / / /
AAChange, amino acid change; B, Benign; CFD, cerebral folate deficiency; D, Damaging; SNV, single nucleotide variant; T, Tolerant.
Figure 1 identification of CiC de novo variants in two CFD sibships. (a) Pedigree of Family 1. (B) Pedigree of Family 2. (C) sequence chromatogram of 
Family 1 proband and her parents. (D) sequence chromatogram of Family 2 proband and the health sibling. CFD, cerebral folate deficiency.
Statistical analysis
Graphics were performed with Excel (Microsoft Excel, V.16.27). 
Statistical analysis was performed with R (R Core Team, 2013). 
Data are presented as mean±SE of the mean. All data were anal-
ysed using two- tailed t- test.
RESULTS
De novo variants identified in patients with CFD
WES was performed on DNA samples from eight CFD family 
trios. Eight de novo variants (DNVs) were discovered in seven 
different trios (table 1). Among these DNVs, six were identi-
fied as de novo missense mutations, and the other two were 
identified as start loss and stop gain mutations. Four of the six 
missense variants were predicted to be damaging using Poly-
phen or SIFT software.35 36 We next examined the function 
of the genes which have putatively deleterious mutations and 
found that three (ATP1A1, SLC35A2, ABCA12) of the six genes 
are associated with an active transport pathway. Among these 
genes, two have already been linked to neuro- related diseases. 
Mutations in ATP1A1 gene, which encodes the alpha-1 isoform 
of the Na(+),K(+)- ATPase, were previously associated with 
autosomal dominant axonal Charcot- Marie- Tooth disease type 
2DD (CMT2DD; OMIM: 618036)45 as well as the hypomag-
nesemia and intractable seizures associated with severe intellec-
tual disability (HOMGSMR2; OMIM: 618314).46 SLC35A2 is 
known to transport uridine 5- prime- diphosphate- galactose from 
the cytoplasm to the Golgi.47 Mutations in SLC35A2 were asso-
ciated with early infantile epileptic encephalopathy-22 (EIEE22; 
OMIM: 300896).48 These results suggest that different muta-
tions in known disease- related active transport genes may have 
different downstream clinical impact on patients.
Among the two putative LoF (loss of function) variants, 
one locates in the RGPD2 gene (NM_001078170:c.T2C:p.
M1T), which encodes a nucleoporin member that has not yet 
been linked to any known disease. However, other nucleoporin 
proteins have previously been associated with multiple human 
diseases, including Down Syndrome and B- ALL.49 It is interesting 
to further explore whether this start loss mutation contributes to 
the CFD aetiology. The other LoF mutation locates at CIC gene 
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Table 2 Summary of all CIC rare mutations identified in gnomAD_freq: data from gnomAD database ‘allele frequency’ (CADD_pred score was 
calculated from https://cadd.gs.washington.edu/score)
Sample Gene Exonic_Function AAChange gnomAD_freq CADD_phred
CFD- 4GS- A CIC Non- synonymous SNV NM_015125:c.C4802T:p.P1601L 8.29E–06 23.4
CFD- B36 CIC Non- synonymous SNV NM_015125:c.G1738T:p.G580C 3.92E–05 23.9
CFD- 1NA CIC Stopgain SNV NM_015125:c.C1057T:p.R353X 0 28.8
CFD- 1SG CIC Frameshift Insertion NM_015125:c.1008_1009InsTG:p.G337GfsX40 0 /
AAChange, amino acid change.
Figure 2 Functional analysis of the CiC variant. (a) Protein amino acid locus of variant p.r353X, which is predicted to create premature stop codons. 
lollipop plot shows all four CiC mutants identified in our CFD cohort.56 (B) localisation of gFP tagged CiC variants in stably transfected hela cells. hela 
cells were transduced with lentiviral particles coding for gFP, gFP- CiC wildtype or gFP- CiC p.r353X. subcellular localisation was analysed by microscopy for 
gFP and endogenous CiC. nuclei were stained with DaPi, Bars, 20 µm. (C) analysis of CiC p.r353X variant effect on interaction between CiC and KPna3. 
Mutant CiC abolished interaction between CiC and KPna3. (D) analysis of CiC p.r353X variant effect on interaction between CiC and aTXn1. CFD, cerebral 
folate deficiency.
previously diagnosed to have signs of autistic spectrum disorder, 
seizures, loss of repetitive language and loss of motor skills.13 
More recently, she was diagnosed as having features consistent 
with a CFD diagnosis. Using WES, we determined that this 
patient lacks rare variants in any known folate transport genes 
(FOLR1, PCFT and DHFR) (allele frequency <0.1% in gnomAD 
dataset). We also sequenced her healthy siblings’ DNA and failed 
to detect the same mutation. To validate mutations in the CIC 
gene that potentially contributes to CFD, we performed WES on 
48 sporadic patients’ DNA. No missense rare variants that were 
previously identified in reported CFD genes were observed. In 
contrast, we identified another three patients with rare puta-
tively deleterious mutations (CADD score >20) in the CIC gene 
in this cohort (table 2). We contacted these three families and 
managed to obtain one (CIC c.1008_1009InsTG) of these three 
mutation carrier’s family members’ DNA samples and performed 
following Sanger sequencing on the CIC gene. The frameshift 
CIC variant (CIC c.1008_1009InsTG) that was identified in the 
patient with CFD was not detected in the parents and her healthy 
sibling (figure 1), indicating that this frameshift mutation is 
another DNM. Compared with the de novo predicted- to- be loss 
of function (LoF), there is a significant (p=7.05×10–5) enrich-
ment of CIC de novo predicted to be LoF variants in patients 
with CFD. Overall, these data suggest a significant enrichment 
of CIC mutations in patients with CFD.
Subcellular localisation and protein-protein interaction
In order to understand the mechanism by which CIC mutations 
could contribute to developing CFD, functional analyses were 
performed using the CIC p.R353X truncated variant. Protein 
domain analysis demonstrated that the CIC p.R353X mutation 
is predicted to create a stop codon before the C2, NLS1 and C1 
domains (figure 2A), which would affect CIC protein nuclear 
localisation. Subcellular localisation assays indicated that wild-
type EGFP- CIC proteins were localised in the nucleus, while 
the p.R353X mutant EGFP- CIC proteins were widely distrib-
uted all over the cells, including the nucleus, cytoplasm and 
cell membrane, similar to the EGFP protein (figure 2B, online 
supplementary figure 1). The variant effect on interactions 
between CIC and KPNA3 or ATXN1 was evaluated by coimmu-
noprecipitation (Co- IP) assays. In the Co- IP assay, the p.R353X 
variant abolished CIC interaction with KPNA3 (figure 2C); 
however, the interaction between mutant CIC (p.R353X) and 
Ataxin1 was still detectable, although it was weaker than the 
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Figure 3 Wildtype CiC regulation of FOlr1, PCFT and rFC1. (a) CiC Dna binding motifs distribution on FOlr1, PCFT and rFC1 gene. FOlr1 has two 
CiC binding motifs in promoter region, while PCF and rFC1 have only one CiC binding motif separately. (B) CiC overexpression by transfecting gFP- CiC 
plasmid and FOlr1, PCFT and rFC1 gene expression detected by qrT- PCr. CiC overexpression significantly increased FOlr1 and PCFT gene expression. (C) 
luciferase assay of FOlr1 promoter indicated that wildtype CiC could stimulate FOlr1 promoter- luciferase expression, while mutant CiC had less ability in 
stimulating FOlr1 promoter- luciferase expression. student's t- test was performed (*p<0.05; **p<0.005). (D) CiC knockdown by anti- CiC sirna (si- CiC) 
and the regulation of three folate transport genes, FOlr1, PCFT and rFC1. student's t- test was performed (*p<0.05). (e) CiC knockdown significantly 
decreased FOlr1 expression. student's t- test was performed (*p<0.05).
CIC binds to promoter region of FOLR1 and regulates FOLR1 
expression
Examination of the CIC DNA binding octamer sequence in the 
FOLR1 promoter region, including two thousand base pairs 
upstream of the transcriptional starting site (+1) indicated that 
there were two CIC binding sites. One octamer (TGAATGAA) 
was located at −1442 bp and the other (TGAATGAA) at −1419 
bp (figure 3A). CIC binding octamers were also located in the 
promoter region of PCFT and RFC1 at −1243~−1236 bp and 
−1926~−1919 bp, respectively (figure 3A). The ChIP assay 
demonstrated that CIC physically binds to the promoter region 
of FOLR1, PCFT and RFC1. Compared with IgG control anti-
body, CIC antibody enriched 4.1- fold more targeted FOLR1 
promoter DNA, 13.8- fold more targeted PCFT promoter DNA 
and 4.2- fold more targeted RFC1 promoter DNA (figure 3B). 
To determine whether CIC could regulate FOLR1 promoter 
activity, we cotransfected HeLa cells with two distinct FOLR1 
promoter constructs (FR1 P4 or FR1 P1+P4) and either GFP- 
CIC wildtype, GFP- CIC mutant or GFP- pLVX. Both FOLR1 
promoter constructs contain the putative CIC binding sites. The 
luciferase activity was significantly increased for both FOLR1 
promoter constructs cotransfected with CIC wildtype (2.6- fold), 
whereas the effect was much smaller for CIC p.R353X variant 
(1.5–1.8- fold; figure 3C), suggesting that CIC regulates FOLR1 
expression. Upregulating CIC by transfecting 500 ng GFP- CIC 
wildtype plasmid into HEK293T cells increased FOLR1, PCFT 
and RFC1 gene expression by 2.8- fold, 1.5- fold and 1.2- fold, 
respectively (figure 3D). Downregulating 43% of CIC expres-
sion by siRNA transfection significantly reduced FOLR1 and 
RFC1 expression by 20% (figure 3E).
CIC variant downregulated FOLR1 expression in cell lines
To determine whether the p.R353X variant could affect expres-
sion of folate transport genes, we generated stable HeLa and 
Caco-2 cell lines expressing GFP, GFP- CIC wildtype and GFP- 
CIC p.R353X.
In HeLa cells, both western blotting and qRT- PCR assays 
demonstrated that wildtype GFP- CIC increased FOLR1 expres-
sion by 2.2 x fold (p<0.01) compared with GFP controls, 
while mutant GFP- CIC decreased FOLR1 expression by 51% 
(p<0.05) compared with GFP controls. PCFT and RFC1 expres-
sion was not significantly (p>0.05) altered in the transfected 
cells (figure 4A–C). The effect of CIC variant downregulation 
on FOLR1 expression in comparison to CIC wildtype was 
confirmed in Caco-2 cells (figure 4D–F).
CIC variants downregulated FOLR1 expression in patient 
iPSCs
To determine whether the CIC variant downregulated FOLR1 
expression in patient cells, we collected fibroblast cells from the 
original CFD proband and generated iPSCs. Sanger sequencing 
indicated that both a wildtype and a mutant copy of the CIC 
gene was observed (figure 5A), suggesting that nonsense medi-
ated decay failed to remove all of the mutant mRNAs. qRT- PCR 
assays demonstrated that the CIC variant downregulated FOLR1 
gene expression by 47% in the proband iPSC compared with 
control iPSCs (figure 5B). Immunoblotting assay indicated that 
CIC variant downregulated FOLR protein expression by 37% in 
the iPSCs comparison (figure 5C,D). PCFT and RFC1 were also 
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Figure 4 Wildtype and mutant CiC regulated the transcription of FOLR1 in stably transfected hela cells. (a) hela cells were transduced with lentiviral 
particles coding for gFP, gFP- CiC wildtype or gFP- CiC p.r353X. representative western blots of endogenous FOlr1 (Frα), PCFT and rFC1 and 
overexpressed gFP- CiC. β-actin was used as a loading control. (B) Protein quantification of FOlr1, PCFT and rFC1 relative to gFP transfected hela cells 
(normalised against β-actin, n=3). (C) Quantification of FOlr1, PCFT and rFC1 mrna levels in hela cells, stably transfected with gFP, gFP- CiC WT or gFP- 
CiC p.r353X. expression was normalised against gaPDh (n=3). (D) Caco-2 cells were transduced with lentiviral particles coding for gFP, gFP- CiC wildtype 
or gFP- CiC p.r353X. representative western blots of CiC and endogenous FOlr1 expression. B- actin was used as loading control. (e) Protein quantification 
of FOlr1 relative to gFP transfected Caco-2. (F) Protein localisation of wildtype and mutant type gFP- CiC in Caco-2 cells. Bars, 10 µm.
Figure 5 Family 1 proband iPsC’s CiC expression and its regulation on folate transporters. (a) Family 1 proband (F1prob) iPs cell Dna sequencing and 
cDna sequencing chromatogram indicated that mutant CiC mrna was less than wildtype CiC mrna. (B) qrT- PCr analysis of CiC, FOlr1, PCFT and rFC1 in 
family 1 proband iPsCs and control iPsCs. (C) immunoblotting analysis of CiC, FOlr1, PCFT and rFC1 protein expression in F1prob iPsCs and control iPsCs. 
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Figure 6 effect of CiC variants on binding of folic acid and cellular folate concentration. (a) Folic acid surface binding by hela cells stably expressing gFP, 
gFP- CiC WT or gFP- CiC p.r353X. Cells were exposed to 5 nmol/l [3h] folic acid binding was calculated relative to gFP transfected cells (n≥3, each carried 
out in duplicate), **p<0.01. (B) Folate concentration in control iPsCs and family 1 proband iPsCs, *p<0.05.
Figure 7 Family 1 proband serum FOlr1 autoantibody measurements in 2005. (a) igg FOlr1 autoantibody measurement during 2005. (B) Fa blocking 
autoantibody measured in 300 days. Both autoantibody concentration and blocking of Fa binding were fluctuating throughout the measurement time 
points.
levels (figure 5B) and by 35% and 33% in their protein concen-
trations (figure 5C,D).
Folic acid binding assay
The FA surface binding activity of HeLa cells stably expressing 
GFP, GFP- CIC WT or GFP- CIC p.R353X was determined 
(figure 6A). As expected, the CIC p.R353X variant reduced 
HeLa cells ability to bind FA by twofold (p<0.01) compared 
with wildtype GFP- CIC. The concentration of folate in iPSCs 
derived from the patient was also determined (figure 6B). Folate 
concentration was decreased by 25% (p<0.05) in iPSCs derived 
from the CIC p.R353X variant carrier when compared with 
iPSCs derived from a control donor lacking the CIC LoF variant 
(figure 6B).
FOLR1 autoantibody analysis
Multiple serum samples were collected from the patient with 
CFD and tested using the previously described microELISA 
assays for the detection of autoantibodies to FOLR1 and inhi-
bition of FA binding to FOLR1.41 All samples tested positive for 
IgG autoantibodies to FOLR1, but the relative concentration of 
IgG was variable (patient range 1.7–52.2) over time (days 1, 8, 
15, 22, 64, 131, 134, 236 and 293) (figure 7A). The blocking 
of FA uptake and binding by patient serum was also variable 
(0.63–1.77 ng/mL) over the same timepoints (figure 7B). The 
concentration of IgG levels was not correlated with the serum 
blocking of FA binding to FOLR1 (Pearson r=0.03, p=0.94).
DISCUSSION
In this study, we did the first trio- based genetic analysis on 
patients with CFD and identified mutations in CIC genes that 
may play important roles in determining CFD risk. Using func-
tional biochemistry assays, we were able to demonstrate a novel 
genetic aetiology of CFD, which we believe is mediated through 
regulating FOLR1 gene expression secondary to mutations in 
CIC. Previous studies indicated that the DNA variants in the 
folate receptor (ie, FOLR1), folate transporter (ie, PCFT) and 
genes involved in folate metabolism (ie, DHFR) can influence 
folate uptake and produce the CFD phenotype. We have now 
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or metabolism yet contributes to the development of CFD. 
Active transport genes were known to be highly associated with 
genetic diseases, while the CIC gene is not directly involved in 
any uptake or transport pathway, yet it can contribute to the 
development of CFD through the regulation of FOLR1 and 
other genes involved in choroid plexus epithelial folate uptake. 
Several potential mechanisms could contribute to the lower 
expression of FOLR1 caused by the CIC mutant. CIC variants 
could prevent CIC nuclear localisation. Second, CIC variants 
could affect CIC’s DNA binding ability and inefficient promoter 
transcription as demonstrated by the luciferase assay (figure 3). 
Another possible scenario involves the malfunctioning mutant 
CIC protein binding to FOLR1 promoter to prevent wildtype 
CIC from binding to DNA, although this is less likely the case 
for CIC p.R353X, as the nuclear translocation of mutant CIC is 
impaired by the variant.
The difference between the CIC variant associated with 
CFD and FOLR1 mutations that have been previously reported 
to cause CFD is that the FOLR1 mutations were reported to 
produce a very severe CFD (CSF 5- MTHF<5 nmol) pheno-
type, while the deleterious mutations in CIC had a more mild 
impact (CSF 5- MTHF: 20–30 nmol). The possibility that other 
genes, including other transcription factors, and cellular inter-
actions indirectly related to folate uptake and metabolism can 
increase the risk of CFD, suggests that the underlying aetiolo-
gies of CFD includes secondary or tertiary modifiers of folate 
uptake, and that these may result in less severe phenotypes.
Since the initial discovery of CIC in 2000, scientists have 
continued to learn the extent of CIC‘s involvement in many 
diverse cellular pathways, including impact on proliferation, 
cancer initiation, tumour development and metastasis.50 The 
observation that CIC binds to the promoter region of FOLR1 
indicates a new function for CIC, that is, the regulation of 
FOLR1 gene expression and regulation of genes related to 
folate uptake and metabolism. It is well established that CIC 
is a transcriptional repressor.14 In this study, we demonstrated 
that CIC functioned as a transcription activator of FOLR1. 
Increased amounts of CIC protein promoted FOLR1 expres-
sion, while decreased CIC expression resulting from siRNA 
silencing reduced FOLR1 gene expression. The change in gene 
expression was also found in protein levels, and by regulating 
the amount of FOLR1 available, CIC is expected to thereby 
modify CSF folate concentrations. To date, several early devel-
opmental phenotypes, such as lung alveolarisation, ompha-
locele and gut malformations observed in germline Cic KO 
mice have not been previously associated with CIC variants in 
human studies. These phenotypes may also be influenced by 
folate availability, similar to CFD, so we propose searching for 
CIC variants in human subjects with comparable malformations 
and attempt to prevent the recurrence of these malformations 
in CIC mutant embryos via maternal folate supplementation.
It was previously reported that high titres of FOLR1 auto-
antibody are associated with the CFD phenotype and can 
functionally block the ability of FOLR1 to bind and transport 
folates.8 CIC deficiency was previously reported to promote T 
cell differentiation and induce autoimmunity,26 so we expected 
to detect FOLR1 autoantibody in the CIC p.R353X carrier. 
However, we observed that the serum FOLR1 autoantibody 
levels varied at different time points. This result is consistent 
with an earlier report by Ramaekers and coworkers on the 
variable levels of FOLR1 autoantibodies over time.51 Autoan-
tibodies to FOLR1 were also reported to respond to folate 
supplementation, so folate serum concentrations may be a 
modifier of FOLR1 autoantibodies and FOLR1 expression.52 53 
It has also been reported that folate supplementation results 
in a loss of significant correlations between folate, homo-
cysteine and autoantibodies concentrations.53 The lack of 
correlation between autoantibodies in this patient and serum 
blocking of FOLR1- folate binding indicates that autoanti-
bodies, serum and CFD folate concentrations may vary over 
time and thereby influence day to day physiology, such that 
the impact of FOLR1 and CIC on CFD should be examined on 
more than one occasion in order to avoid detection of spurious 
depressed or elevated readings. A large CFD- control cohort 
with multiple sampling time points for folate, CSF folate, 
and FOLR1 autoantibody data are required to best determine 
whether CIC deficiency also increases the risk of FOLR1 auto-
antibodies and thereby also contributes to CFD risk.
Current studies on CIC molecular interactions are not suffi-
cient to provide explanations for the range of phenotypic vari-
ations that were observed among patients carrying different 
CIC LoF variants. We previously reported five patients with 
CIC mutations, whose most consistent clinical features were 
development delay and intellectual disability, as all five patients 
shared these characteristics.13 The other documented pheno-
types were only present in a portion of the CIC truncating 
mutation carriers. The initial patient with CFD (p.R353X 
carrier) had B- cell ALL and was treated with MTX for 2 
years, while the second patient with CFD (p.1008_1009InsTG 
carrier) identified in the validation studies, did not present 
with any cancer pathology. No CSF samples were available 
from the other four CIC LoF variants carriers described in 
our previous paper,13 so we do not know whether they also 
had low folate CSF concentrations. The different phenotypes 
observed among different CIC LoF carriers may be due to 
a combination of different factors, including genetic back-
ground and ability to uptake folate, as well as different envi-
ronmental exposures. We checked GeneMatcher54 data and 
found 16 LoF CIC variants records. Based on previous CFD 
studies,55 it may be helpful for medical researchers and clinical 
care providers of CIC carrier patients to examine tissue folate 
levels and consider examination of folate supplementation in 
patients, especially if 5- MTHF concentrations are significantly 
lower than the normal range in serum or CSF.
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